|
|
|
|
| LEADER |
00000cam a2200000Ma 4500 |
| 001 |
EBSCO_ocn969643048 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
170121s2017 nyu o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCO
|d OCLCQ
|d N$T
|d OCLCF
|d AGLDB
|d IGB
|d AUW
|d BTN
|d MHW
|d INTCL
|d SNK
|d G3B
|d S8I
|d S8J
|d S9I
|d STF
|d D6H
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 966445399
|
| 020 |
|
|
|a 9781536105346
|
| 020 |
|
|
|a 1536105341
|
| 020 |
|
|
|z 9781536105124
|
| 035 |
|
|
|a (OCoLC)969643048
|z (OCoLC)966445399
|
| 050 |
|
4 |
|a RC267
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.99/4
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Horizons in Cancer Research.
|n Volume 64.
|
| 260 |
|
|
|a New York :
|b Nova Science Publishers, Inc.,
|c 2017.
|
| 300 |
|
|
|a 1 online resource (231 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Horizons in Cancer Research
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Preface; Chapter 1; Impact of Personalized Medicine in Cancer; Abstract; Introduction; Foundation of Personalized Medicine; Pharmacogenetics; Pharmacodynamics; Pharmacokinetics; Pharmacokinetics or Pharmacodynamics; Pharmacogenomics; Toxicogenomics; Metabonomics; Pharmacoproteomics; Personalized Medicine in Cancer; Conclusion; Acknowledgments; Conflict of Interest; References; Chapter 2; Malignant Mesothelioma; Abstract; Introduction; Risk Factors; Asbestos; People Most at Risk of an Asbestos-Related Disease?; Non-Occupational Exposure; Treatment; Preventive Measures.
|
| 505 |
8 |
|
|a Curative MeasuresSurgical; A. Malignant Mesothelioma of Tunica Vaginalis:; B. Malignant Pleural Mesothelioma; Chemotherapy; Radiotherapy; Recommendation; Targeted Therapy; Gene Therapy; Photodynamic Therapy; Immunotherapy; Virus Therapies; References; Chapter 3; The Role of Heat-Shock Proteins and Chaperonins in the Pathogenesis and Progression of Cancer; Abstract; Introduction; Molecular Chaperones; Chaperonins; Chaperones and Cancer; Hsp90; Hsp70; Hsp27; Chaperonins and Cancer; Overall Architecture of Chaperonins; CCT/TRiC and Cancer; Hsp60; Molecular Chaperones and the Immune Response.
|
| 505 |
8 |
|
|a AcknowledgmentsReferences; Chapter 4; Biosynthesis of Lex Family Glycosphingolipids and its Gene Regulation: XIV. in Apoptotic Breast Carcinoma Cells; Abstract; Introduction and Discussion; Betulin and Betulinic Acid as Apoptotic Agents in Cancer Cells; Proper Drug Delivery Systems are Required to Kill Specific Cancer Cells; Summary; Acknowledgment; References; Chapter 5; Chromosome Instability as a Target for Cancer Therapeutics: Challenges of Mitotic Inhibitors; Abstract; Introduction; 1. The Spindle Assembly Checkpoint Maintains the Fidelity of Chromosome Segregation.
|
| 505 |
8 |
|
|a 1.1. Chromosome Segregation in Mitosis1.2. Spindle Assembly Checkpoint Machinery; 1.3. SAC Attenuation and Cancer; 2. Aneuploidy and Cancer; 2.1. Aneuploidy in Colorectal Cancer; 2.2. Aneuploidy in Ovarian Cancer; 2.3. Aneuploidy in Gastric Cancer; 3. Chromosome Dynamics and Cancer Therapeutics; 3.1. Microtubule-Targeting Agents; 3.2. Microtubule-Stabilizing Agents; 3.3. Microtubule-Destabilizing Agents; 3.4. Side Effects of Microtubule Inhibitors; 3.5. Target Molecule Inhibitors of Mitotic Components; 3.5.1. Aurora Kinase Inhibitors; 3.5.2. Polo-Like Kinase (PLK) Inhibitors.
|
| 505 |
8 |
|
|a 3.5.3. EG5 Inhibitors3.5.4. Centromere-Associated Protein-E (CENP-E) Inhibitors; Conclusion; Disclosure of Potential Conflict of Interest; References; Chapter 6; CD26-Targeted Therapy: A New Horizon in Malignant Pleural; Mesothelioma Management; Abstract; Introduction; Molecular Characterization of CD26; CD26 and Immune Function; Expression of CD26 in MPM; Clinical Relevance of CD26 Expression and MPM; MPM Cancer Cell Biology of CD26; CD26 and Cancer Stem Cells in MPM; Association of CD26 and Extracellular Matrix in MPM.
|
| 500 |
|
|
|a Preclinical Proof-of-Concept (POC) Study of Anti-CD26 mAb Therapy for MPM.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Cancer
|x Research.
|
| 650 |
|
0 |
|a Cancer
|x Treatment.
|
| 650 |
|
6 |
|a Cancer
|x Recherche.
|
| 650 |
|
6 |
|a Cancer
|x Traitement.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Cancer
|x Research
|2 fast
|
| 650 |
|
7 |
|a Cancer
|x Treatment
|2 fast
|
| 700 |
1 |
|
|a Watanabe, Hiroto S.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Watanabe, Hiroto S.
|t Horizons in Cancer Research. Volume 64.
|d Hauppauge : Nova Science Publishers, Inc., ©2017
|z 9781536105124
|
| 830 |
|
0 |
|a Horizons in cancer research.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1441599
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4787087
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1441599
|
| 994 |
|
|
|a 92
|b IZTAP
|
